Alembic Pharma CFO On Strong Growth, Margin Expansion And US Outlook
NDTV Profit · 05 Nov 2026 · 4 min
Management interview of Alembic Pharmaceuticals Ltd (APLLTD), with 6 key numbers discussed.
- G Krishnan, Chief Financial Officer, Alembic Pharmaceuticals
Alembic Pharmaceuticals posted strong Q2 results, driven by 36% broad-based revenue growth and operating margin expansion of 500 bps to 22%. Performance was aided by core volume growth, operating leverage, and US launches, including Bosutinib. For the full year FY27, management raised expectations, guiding for consolidated revenue growth of 20-25% and US growth of up to 40%. Full-year EBITDA margins are expected to settle in the high-teen range while absorbing R&D spends of 8-9% of revenue and investments in the US branded business.